William Stohl1, Jean L Scholz, Michael P Cancro. 1. Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: BLyS family ligands and receptors are key players in the selection and survival of most mature B lymphocytes. The fundamental role of BLyS in transitional B cell selection, coupled with the relative BLyS-independence of memory B cells and plasma cells, suggests that BLyS may be a useful therapeutic target in strategies directed against preimmune B cell pools. Several agents that target BLyS are in clinical trials now, and we summarize recent results here, with a focus on systemic lupus erythematosus (SLE). RECENT FINDINGS: Belimumab, a human neutralizing anti-BLyS monoclonal antibody, has delivered moderate but positive results in two separate phase III clinical trials for SLE, and was recently recommended for approval by an FDA advisory panel. Additional agents targeting BLyS or other members of this cytokine receptor family are also being tested in clinical trials. SUMMARY: Together, these trials should yield novel therapies for a debilitating and often intractable illness and offer insights that in turn should foster subsequent generations of personalized, targeted therapies for rheumatic diseases.
PURPOSE OF REVIEW: BLyS family ligands and receptors are key players in the selection and survival of most mature B lymphocytes. The fundamental role of BLyS in transitional B cell selection, coupled with the relative BLyS-independence of memory B cells and plasma cells, suggests that BLyS may be a useful therapeutic target in strategies directed against preimmune B cell pools. Several agents that target BLyS are in clinical trials now, and we summarize recent results here, with a focus on systemic lupus erythematosus (SLE). RECENT FINDINGS:Belimumab, a human neutralizing anti-BLyS monoclonal antibody, has delivered moderate but positive results in two separate phase III clinical trials for SLE, and was recently recommended for approval by an FDA advisory panel. Additional agents targeting BLyS or other members of this cytokine receptor family are also being tested in clinical trials. SUMMARY: Together, these trials should yield novel therapies for a debilitating and often intractable illness and offer insights that in turn should foster subsequent generations of personalized, targeted therapies for rheumatic diseases.
Authors: Robin Lesley; Ying Xu; Susan L Kalled; Donna M Hess; Susan R Schwab; Hong-Bing Shu; Jason G Cyster Journal: Immunity Date: 2004-04 Impact factor: 31.745
Authors: J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg Journal: Nature Date: 2000-04-27 Impact factor: 49.962
Authors: Viktor Roschke; Svetlana Sosnovtseva; Christopher D Ward; June S Hong; Rodger Smith; Vivian Albert; William Stohl; Kevin P Baker; Stephen Ullrich; Bernardetta Nardelli; David M Hilbert; Thi-Sau Migone Journal: J Immunol Date: 2002-10-15 Impact factor: 5.422
Authors: T Koyama; H Tsukamoto; Y Miyagi; D Himeji; J Otsuka; H Miyagawa; M Harada; T Horiuchi Journal: Ann Rheum Dis Date: 2004-12-02 Impact factor: 19.103
Authors: Kevin P Baker; Bryan M Edwards; Sarah H Main; Gil H Choi; Ruth E Wager; Wendy G Halpern; Patrick B Lappin; Todd Riccobene; Donara Abramian; Les Sekut; Bonnie Sturm; Carol Poortman; Ralph R Minter; Claire L Dobson; Elizabeth Williams; Sara Carmen; Rodger Smith; Viktor Roschke; David M Hilbert; Tristan J Vaughan; Vivian R Albert Journal: Arthritis Rheum Date: 2003-11
Authors: Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle Journal: J Exp Med Date: 2004-01-05 Impact factor: 14.307
Authors: Vishal J Sindhava; Michael A Oropallo; Krishna Moody; Martin Naradikian; Lauren E Higdon; Lin Zhou; Arpita Myles; Nathaniel Green; Kerstin Nündel; William Stohl; Amanda M Schmidt; Wei Cao; Stephanie Dorta-Estremera; Taku Kambayashi; Ann Marshak-Rothstein; Michael P Cancro Journal: J Clin Invest Date: 2017-03-27 Impact factor: 14.808
Authors: Jolan E Walter; Mindy S Lo; Katalin Kis-Toth; Irit Tirosh; Francesco Frugoni; Yu Nee Lee; Krisztian Csomos; Karin Chen; Shiv Pillai; Jonathan Dunham; George C Tsokos; Eline T Luning Prak; Luigi D Notarangelo Journal: J Allergy Clin Immunol Date: 2014-10-11 Impact factor: 10.793
Authors: Danielle Malheiros; Rodrigo A Panepucci; Ana M Roselino; Amélia G Araújo; Marco A Zago; Maria Luiza Petzl-Erler Journal: Immunology Date: 2014-11 Impact factor: 7.397